heliosDX Announces Pursuit of TSX-V Listing and Roadmap Update

ALPHARETTA, GA / ACCESSWIRE / August 17, 2021 /RushNet, Inc (OTC PINK:RSHN), ("the Company") with its subsidiary heliosDX, is pleased to announce the pursuit of listing on the TSX Venture Exchange in conjunction with contemplated split-off efforts currently underway in the US. TSXV is the venture affiliate of the Toronto Stock Exchange. We are in the early stages of this effort but, to that end, have engaged qualified counsel to proceed with such "uplisting."

heliosDX feels that the endeavor to list on the TSX-V further enhances the company's credibility within the public forum while increasing shareholder value for both Rushnet and the future heliosDX publicly traded entity.

The benefits of the listing we will be pursuing, if successful, should allow heliosDX to:

• Provide additional liquidity to be used towards funding of future acquisitions and growth;
• Enhances heliosDX ability to reach our future target of $50 million in annual revenue by EOY 2023;
• Continued growth and exposure in the public sector in the U.S., Canadian and, in due course, world markets; and
• We also believe that increased liquidity will follow assuming (as we do) that heliosDX is accepted and listed on TSX-V.

In the immediate future, heliosDX will be reviewing and completing all TSX-V listing requirements. This process started the week of August 9, 2021. We will update this process as events permit.

Admittedly, the process for heliosDX in the United States has taken a bit longer than expected to become a fully reporting (and audited) standalone publicly traded entity. There have been a few unexpected hurdles we've had to overcome. The good news is that we believe we've overcome the hurdles and the process moves forward. Upon completion of the SEC-qualified split-off, the RushNet, Inc. shareholders will maintain significant value in heliosDX through an enhanced dividend and it considers uplisting in the United States as well..

Mr. Ashley Sweat, CEO of heliosDX and RushNet respectively, says, "I could not be more pleased with the progress we've made in under 6 months. We have acted quickly and decisively, and the accomplishments stand for themselves in our in process roadmap thus far".

Completed:

• Filing Disclosures
• Filing Financials
• Attorney Letter
• Mid/2nd Quarter Financial Update (Record Breaking)
• Pink Current
• Website transition chattahoocheelabs.com to heliosDX.com
• Professional Sales and Marketing Video
• R/S Officially Canceled
• Opened Executive Offices in Jacksonville, FL
• Names first Board Member (Scott Wakeman)
• Hired a New COO (Yann Gerville-Reache)
• Hired a Director of Virtual Sales (Aimee Matlock)
• Launched National Sales Campaign Utilizing Verb Technologies
• Acquisition of heliosDX
• Acquisition of Grandeza Healthcare
• 30 Second Commercial Spot to be Launched Primetime Nationally on CNN, Fox News, Fox Business, Bloomberg, CNBC, MSNBC

Even with the vigorous efforts and time to restructure to bring heliosDX to the public market, we have still continued our significant growth MoM, QoQ, and YoY. Specifically, heliosDX had annual revenues in 2019 of $2,600,000; revenues in 2020 of $4,290,000; and, in 2021, we expect our revenues to exceed $6,000,000. This has occurred, we believe, because we remain focused on our core business, while expanding to new testing methodologies. This is a direct correlation to setting new revenue benchmarks for three consecutive quarters.

Mr. Sweat also just conducted a second interview with New to the Streets to be aired nationally on Newsmax, Fox Business and Bloomberg.

About HeliosDx:

heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. We intend to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In management's opinion, following such best practices are intended to allow heliosDX to provide physicians fast and accurate reporting, meeting and exceeding industry benchmarks. It is our goal to excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.

Contact:

Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: RushNet, Inc.